SA518391973B1 - تركيبات ومجموعات تشتمل على مستقبلات خلية ناتجة عن عودة الارتباط الجيني وطرق ‏استخدام مستقبلات خلية ‏t‏- ‏ ناتجة عن عودة الارتباط الجيني ‏t- - Google Patents

تركيبات ومجموعات تشتمل على مستقبلات خلية ناتجة عن عودة الارتباط الجيني وطرق ‏استخدام مستقبلات خلية ‏t‏- ‏ ناتجة عن عودة الارتباط الجيني ‏t-

Info

Publication number
SA518391973B1
SA518391973B1 SA518391973A SA518391973A SA518391973B1 SA 518391973 B1 SA518391973 B1 SA 518391973B1 SA 518391973 A SA518391973 A SA 518391973A SA 518391973 A SA518391973 A SA 518391973A SA 518391973 B1 SA518391973 B1 SA 518391973B1
Authority
SA
Saudi Arabia
Prior art keywords
recombinant
cell receptors
methods
libraries
cells
Prior art date
Application number
SA518391973A
Other languages
English (en)
Inventor
اديكونل اودونسي،
تاكيماسا تسوجي،
جونكو ماتسوزاكي،
Original Assignee
هيلث ريسيرش، انك.‏
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by هيلث ريسيرش، انك.‏ filed Critical هيلث ريسيرش، انك.‏
Publication of SA518391973B1 publication Critical patent/SA518391973B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم بولي نيوكليوتيدات ناتجة عن عودة الارتباط الجيني ‏recombinant ‎polynucleotides، بما في ذلك نواقل التعبير الوراثي ‏expression vectors‏ التي تشفر سلسلة ألفا ‏alpha chain‏ و/أو سلسلة بيتا ‏beta chain‏ من مستقبل خلية ‏T‏ ‏T Cell‏ ‏Receptors‏ ‏‎(TCR)‎‏ به ‏متواليات حمض أميني ‏amino acid‏ من أي مستقبلات خلية ‏T‏ ‏T Cell‏ ‏Receptors ‎‏ ‏‎(TCRs) ‎‏ من ‏AL، ‏KQ، ‏PP، ‏‎19305CD8‎، ‏BB، ‏KB، ‏ST، ‏JD، ‏‎19305DP‎، ‏PB-P، ‏PB-T، وPB13.2‎‏ جديد ‏تمثل تجسيدات من الاختراع. ويتم تقديم خلايا تشتمل على البولي نيوكليوتيدات، كمجموعات من ‏البولي نيوكليوتيدات الناتجة عن عودة الارتباط الجيني ونواقل التعبير الوراثي. يتم تقديم الطرق ‏وتنطوي على إعطاء إلى خلايا ‏T‏ بشرية معدلة ‏modified human T cells‏ فردية تعبر عن مستقبل ‏خلية ‏T‏ ناتج عن عودة الارتباط الجيني جديد. وتكون الطرق للمعالجة الوقائية و/أو المداواة لفرد تم ‏تشخيصه بأنه مصاب، مشكوك بأنه يعاني من أو يتعرض لمخاطر تطور أو إعادة حدوث سرطان، ‏حيث يتضمن الخلايا السرطانية ‏cancer cells‏ سرطانية تعبر عن ‏NY-ESO-1‎‏ و/أو مولد ضد ‏LAG
SA518391973A 2016-01-06 2018-07-04 تركيبات ومجموعات تشتمل على مستقبلات خلية ناتجة عن عودة الارتباط الجيني وطرق ‏استخدام مستقبلات خلية ‏t‏- ‏ ناتجة عن عودة الارتباط الجيني ‏t- SA518391973B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275600P 2016-01-06 2016-01-06
PCT/US2017/012464 WO2017120428A2 (en) 2016-01-06 2017-01-06 Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors

Publications (1)

Publication Number Publication Date
SA518391973B1 true SA518391973B1 (ar) 2021-11-25

Family

ID=59274283

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518391973A SA518391973B1 (ar) 2016-01-06 2018-07-04 تركيبات ومجموعات تشتمل على مستقبلات خلية ناتجة عن عودة الارتباط الجيني وطرق ‏استخدام مستقبلات خلية ‏t‏- ‏ ناتجة عن عودة الارتباط الجيني ‏t-

Country Status (11)

Country Link
US (1) US11020431B2 (ar)
EP (1) EP3399985B1 (ar)
JP (1) JP6895975B2 (ar)
CN (1) CN108778291B (ar)
AU (1) AU2017205637B2 (ar)
CA (1) CA3010416A1 (ar)
DK (1) DK3399985T3 (ar)
ES (1) ES2909150T3 (ar)
RU (1) RU2752528C2 (ar)
SA (1) SA518391973B1 (ar)
WO (1) WO2017120428A2 (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3010416A1 (en) 2016-01-06 2017-07-13 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
KR102375218B1 (ko) 2016-12-08 2022-03-17 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
CN111819194B (zh) * 2018-02-26 2024-06-04 基因医疗免疫疗法有限责任公司 Nyeso t细胞受体(tcr)
US20210000873A1 (en) * 2018-03-01 2021-01-07 University Of Kansas Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
WO2019217831A1 (en) * 2018-05-11 2019-11-14 Memorial Sloan-Kettering Cancer Center Methods for identifying antigen-specific t cell receptors
CN112585162A (zh) * 2018-08-06 2021-03-30 基因医疗免疫疗法有限责任公司 Ha-1特异性t细胞受体及其用途
AU2019394940A1 (en) * 2018-12-05 2021-06-24 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
AU2020231106A1 (en) * 2019-03-04 2021-10-07 University Health Network T cell receptors and methods of use thereof
CN113906141A (zh) * 2019-03-04 2022-01-07 大学健康网络 T细胞受体及其使用方法
US20220168345A1 (en) * 2019-03-04 2022-06-02 University Health Network T cell receptors and methods of use thereof
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
WO2021148110A1 (en) * 2020-01-21 2021-07-29 Lion Tcr Pte. Ltd. Hbv specific tcr library and its use as personalised medicine
WO2024112957A1 (en) * 2022-11-23 2024-05-30 Amber Bio Inc. Gene-modifying endonucleases
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK17332000A3 (sk) * 1998-05-19 2001-06-11 Avidex Limited Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby
AU2003214566A1 (en) * 2002-03-14 2003-09-22 Anosys, Inc. Functionalization of T cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2007032255A1 (ja) * 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
JP5292550B2 (ja) 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US8603810B2 (en) 2008-05-09 2013-12-10 Agency For Science, Technology And Research T-cell having a T-cell receptor that recognizes epitope HBC18-27 of hepatitis B viral core antigen
RS56339B1 (sr) 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi
WO2014160030A2 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
CA3010416A1 (en) 2016-01-06 2017-07-13 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors

Also Published As

Publication number Publication date
AU2017205637A1 (en) 2018-07-26
US20190275081A1 (en) 2019-09-12
CA3010416A1 (en) 2017-07-13
JP2019506154A (ja) 2019-03-07
ES2909150T3 (es) 2022-05-05
AU2017205637B2 (en) 2023-01-05
WO2017120428A3 (en) 2017-11-16
RU2752528C2 (ru) 2021-07-29
RU2018124506A (ru) 2020-02-07
CN108778291A (zh) 2018-11-09
WO2017120428A2 (en) 2017-07-13
EP3399985A4 (en) 2019-07-31
DK3399985T3 (da) 2022-03-21
US11020431B2 (en) 2021-06-01
RU2018124506A3 (ar) 2020-08-18
JP6895975B2 (ja) 2021-06-30
CN108778291B (zh) 2020-11-10
EP3399985B1 (en) 2022-02-23
EP3399985A2 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
SA518391973B1 (ar) تركيبات ومجموعات تشتمل على مستقبلات خلية ناتجة عن عودة الارتباط الجيني وطرق ‏استخدام مستقبلات خلية ‏t‏- ‏ ناتجة عن عودة الارتباط الجيني ‏t-
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
MY196179A (en) T Cell Receptors Specific for the NY-ESO-1 Tumor Antigen-Hla-A*02 Complex
CO2018011972A2 (es) Receptores de células t
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
MX2019008346A (es) Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
EA201790953A1 (ru) Изменение экспрессии гена в cart-клетках и их применения
ZA202306640B (en) T cell receptors
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
CO2019007868A2 (es) Anticuerpos agonistas anti-icos y sus usos
CO2019011688A2 (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame
MX2018007295A (es) Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
MX2021001837A (es) Constructos del receptor de celulas t y usos de los mismos.
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
CR20190278A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
BR112017003104A2 (pt) tratamento de câncer usando um receptor antigênico quimérico anti-cd123
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112016021004A2 (pt) biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula
CY1119854T1 (el) Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου
BR112019005685A2 (pt) células t com resistência à imunossupressão aumentada
EA202192327A1 (ru) T-клеточные рецепторы, специфичные к mage-a4
EA201892217A1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
ES2972783T3 (es) Tratamiento de las neoplasias malignas hematológicas